You just read:

Esperance Pharmaceuticals Announces Completion of Run-in Enrollment of Phase 2 Study of EP-100 Plus Paclitaxel in Advanced Ovarian Cancer

News provided by

Esperance Pharmaceuticals, Inc.

Aug 28, 2012, 07:30 ET